

10. (Amended) A formulation according to claim 1 which is a single infusion dosage form comprising at least 1300 mg of the estramustine phosphate.

11. (Amended) A formulation according to claim 1 which is in single infusion dosage form comprising at least 950 mg/m² of the estramustine phosphate.

12. (Amended) A formulation according to claim 10 wherein the basic amino acid is arginine.

13. (Amended) A formulation according to claim 1 for intravenous use.

14. (Amended) A formulation according to claim 1 for use in the treatment of cancer.

19. (Amended) A product according to claim 17 wherein the chemotherapeutic agent is selected from the group consisting of taxane derivatives such as paclitaxel and docetaxel; camptothecin and derivatives thereof such as CPT-11 and 9-amino-camptothecin; anthracycline derivatives such as doxorubicin, epirubicin, idarubicin, daunorubicin, alkylcyclo (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyl-daunorubicin; internal code PNU 159548); etoposide; navelbine; vinblastine; platinum derivatives such as carboplatin and cisplatin; angiogenesis inhibitors such as Sugen SU-5416 and Sugen SU-6668; optionally within liposomal formulations thereof.

Please add the following new claim:

32. (New) The formulation according to Claim 11 wherein the basic amino acid is arginine.